Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France
Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Eileen M. Boyle(BMW (Germany)), Hélène Demarquette, Isabelle Leduc(Centre Hospitalier d'Albi), Thierry Façon(Inserm), Paul Chauvet(Centre Hospitalier Universitaire de Lille), Laurent Pascal(Groupe Hospitalier de l'Institut Catholique de Lille), Pauline Lionne(Centre Hospitalier d'Arras), Alexandre Willaume(Hôpital Saint-Vincent-de-Paul), Benjamin Carpentier, Micha Srour, Charles Herbaux(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Gibier(Institut de Biologie de Lille), Morgane Nudel(Centre Hospitalier Universitaire de Lille), Julia Hieulle(Centre Hospitalier Universitaire de Lille), Michèle Vasseur(Centre Hospitalier Universitaire de Lille), Sarah Barbieux(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Bossard(Centre Hospitalier Universitaire de Lille), Claire Bories(Guy's and St Thomas' NHS Foundation Trust), Arthur Simonnet(Centre Hospitalier Universitaire de Lille)
Cited by 6
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564